Featured Research

from universities, journals, and other organizations

Is Anthrax Just The Beginning?

Date:
October 19, 2001
Source:
Northeastern University
Summary:
Jim Matthews, an associate professor of pharmacy at Northeastern University’s Bouvé College of Health Sciences, says that though the use of anthrax as a bioterrorist weapon is haunting, it is not nearly as frightening as the threat of attacks using smallpox or the bubonic plague.

What could be deadlier than anthrax? Try smallpox and the bubonic plague.

Jim Matthews, an associate professor of pharmacy at Northeastern University’s Bouvé College of Health Sciences, says that though the use of anthrax as a bioterrorist weapon is haunting, it is not nearly as frightening as the threat of attacks using smallpox or the bubonic plague.

“Anthrax is not easily transferred, so to develop it as a weapon is difficult, and in most cases, it responds quite well to antibiotics,” said Matthews. “However, what I would be more fearful and weary of is an outbreak of smallpox or the bubonic plague, caused by terrorist acts. Smallpox, for example, is contagious and there is no effective treatment available. Even as we speak, some federal officials have reason to believe that Iraq is developing it as a biological weapon.”

While Matthews believes that it is important for government to focus its energies on investigating the recent bioterrorist mailings and ensuring the availability of anthrax antibiotics and vaccines, he believes it is imperative that government accelerates work on protection against untreatable viruses.

“It’s great that federal officials are working to have the anthrax antibiotic, Ciprofloxacin readily available for those believed to be infected,” said Matthews. (“Incidentally the only anthrax vaccine manufactured in the U.S. by Michigan-based BioPort Corporation and sponsored by the Department of Defense, is only available through the Center for Disease Control and to members of the military.”)

“However, contingency plans should be in the works to guard against other bioterrorist threats such as smallpox,” warns Matthews.


Story Source:

The above story is based on materials provided by Northeastern University. Note: Materials may be edited for content and length.


Cite This Page:

Northeastern University. "Is Anthrax Just The Beginning?." ScienceDaily. ScienceDaily, 19 October 2001. <www.sciencedaily.com/releases/2001/10/011019074315.htm>.
Northeastern University. (2001, October 19). Is Anthrax Just The Beginning?. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/10/011019074315.htm
Northeastern University. "Is Anthrax Just The Beginning?." ScienceDaily. www.sciencedaily.com/releases/2001/10/011019074315.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins